Amino terminus of the SARS coronavirus protein 3a elicits strong, potentially protective humoral responses in infected patients

References

1. Bisht H., Roberts A., Vogel L., Bukreyev A., Collins P. L., Murphy B. R., Subbarao K., Moss B. 2004; Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Proc Natl Acad Sci U S A 101:6641–6646 [CrossRef]
   [Google Scholar]
2. Buchholz U. J., Bukreyev A., Yang L., Lamirande E. W., Murphy B. R., Subbarao K., Collins P. L. 2004; Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. Proc Natl Acad Sci U S A 101:9804–9809 [CrossRef]
   [Google Scholar]
3. Chang M.-S., Lu Y.-T., Ho S.-T. & 11 other authors 2004; Antibody detection of SARS-CoV spike and nucleocapsid protein. Biochem Biophys Res Comm 314:931–936 [CrossRef]
   [Google Scholar]
4. Chen Z., Pei D., Jiang L. 11 other authors 2004; Antigenicity analysis of different regions of the severe acute respiratory syndrome coronavirus nucleocapsid protein. Clin Chem 50:988–995 [CrossRef]
   [Google Scholar]
5. Chinese SARS Molecular Epidemiology Consortium 2004; Molecular evolution of the SARS coronavirus during the course of the SARS epidemic in China. Science 303:1666–1669 [CrossRef]
   [Google Scholar]
6. Drosten C., Günther S., Preiser W. & 23 other authors 2003; Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 348:1967–1976 [CrossRef]
   [Google Scholar]
7. Gao W., Tamin A., Soloff A., D'Aiuto L., Nwanegbo E., Robbins P. D., Bellini W. J., Barratt-Boyes S., Gambotto A. 2003; Effects of a SARS-associated coronavirus vaccine in monkeys. Lancet 362:1895–1896 [CrossRef]
   [Google Scholar]
8. Guo J.-P., Petric M., Campbell W., McGeer P. L. 2004; SARS corona virus peptides recognized by antibodies in the sera of convalescent cases. Virology 324:251–256 [CrossRef]
   [Google Scholar]
9. He Y., Zhou Y., Wu H., Luo B., Chen J., Li W., Jiang S. 2004; Identification of immunodominant sites on the spike protein of severe acute respiratory syndrome (SARS) coronavirus: implication for developing SARS diagnostics and vaccines. J Immunol 173:4050–4057 [CrossRef]
   [Google Scholar]
10. Ito N., Mossel E. C., Narayanan K., Popov V. L., Huang C., Inoue T., Peters C. J., Makino S. 2005; Severe acute respiratory syndrome coronavirus 3a protein is a viral structural protein. J Virol 79:3182–3186 [CrossRef]
    [Google Scholar]
11. Johnston R. E. 2004; A candidate vaccine for severe acute respiratory syndrome. N Engl J Med 351:827–828 [CrossRef]
    [Google Scholar]
12. Ksiazek T. G., Erdman D., Goldsmith C. S. & 24 other authors 2003; A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 348:1953–1966 [CrossRef]
    [Google Scholar]
13. Leung D. T. M., Tam F. C. H., Ma C. H., Chan P. K. S., Cheung J. L. K., Niu H., Tam J. S. L., Lim P. L. 2004; Antibody response of patients with severe acute respiratory syndrome (SARS) targets the viral nucleocapsid. J Infect Dis 190:379–386 [CrossRef]
    [Google Scholar]
14. Liu X., Shi Y., Li P., Li L., Yi Y., Ma Q., Cao C. 2004; Profile of antibodies to the nucleocapsid protein of the severe acute respiratory syndrome (SARS)-associated coronavirus in probable SARS patients. Clin Diagn Lab Immunol 11:227–228
    [Google Scholar]
15. Peiris J. S. M., Lai S. T., Poon L. L. M. & 14 other authors 2003; Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 361:1319–1325 [CrossRef]
    [Google Scholar]
16. Poutanen S. M., Low D. E., Henry B. & 19 other authors 2003; Identification of severe acute respiratory syndrome in Canada. N Engl J Med 348:1995–2005 [CrossRef]
    [Google Scholar]
17. Rottier P. J. M. 1995; The coronavirus membrane glycoprotein. In The Coronaviridae pp  115–139 Edited by Siddell S. G. New York: Plenum;
    [Google Scholar]
18. Ruan Y., Wei C. L., Ee L. A. & 17 other authors 2003; Comparative full-length genome sequence analysis of 14 SARS coronavirus isolates and common mutations associated with putative origins of infection. Lancet 361:1779–1785 [CrossRef]
    [Google Scholar]
19. Shi Y., Wan Z., Li L., Li P., Li C., Ma Q., Cao C. 2004; Antibody responses against SARS-coronavirus and its nucleocapsid in SARS patients. J Clin Virol 31:66–68 [CrossRef]
    [Google Scholar]
20. Siddell S. G. 1995; The small-membrane protein. In The Coronaviridae pp  181–189 Edited by Siddell S. G. New York: Plenum;
    [Google Scholar]
21. Subbarao K., McAuliffe J., Vogel L. 7 other authors 2004; Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice. J Virol 78:3572–3577 [CrossRef]
    [Google Scholar]
22. Tan Y.-J., Goh P.-Y., Fielding B. C. & 9 other authors (2004a). Profiles of antibody responses against severe acute respiratory syndrome coronavirus recombinant proteins and their potential use as diagnostic markers. Clin Diagn Lab Immunol 11:362–371
    [Google Scholar]
23. Tan Y.-J., Teng E., Shen S. & 7 other authors 2004b; A novel severe acute respiratory syndrome coronavirus protein, U274, is transported to the cell surface and undergoes endocytosis. J Virol 78:6723–6734 [CrossRef]
    [Google Scholar]
24. Wang J., Wen J., Li J. 30 other authors 2003; Assessment of immunoreactive synthetic peptides from the structural proteins of severe acute respiratory syndrome coronavirus. Clin Chem 49:1989–1996 [CrossRef]
    [Google Scholar]
25. Yang Z.-Y., Kong W.-P., Huang Y., Roberts A., Murphy B. R., Subbarao K., Nabel G. J. 2004; A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature 428:561–564 [CrossRef]
    [Google Scholar]
26. Yang Z.-Y., Werner H. C., Kong W.-P., Leung K., Traggiai E., Lanzavecchia A., Nabel G. J. 2005; Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses. Proc Natl Acad Sci U S A 102:797–781 [CrossRef]
    [Google Scholar]
27. Yeh S.-H., Wang H.-Y., Tsai C.-Y. & 8 other authors 2004; Characterization of severe acute respiratory syndrome coronavirus genomes in Taiwan: molecular epidemiology and genome evolution. Proc Natl Acad Sci U S A 101:2542–2547 [CrossRef]
    [Google Scholar]
28. Yu C.-J., Chen Y.-C., Hsiao C.-H. & 9 other authors 2004; Identification of a novel protein 3a from severe acute respiratory syndrome coronavirus. FEBS Lett 565:111–116 [CrossRef]
    [Google Scholar]
29. Zeng R., Yang R.-F., Shi M.-D. & 31 other authors 2004; Characterization of the 3a protein of SARS-associated coronavirus in infected Vero E6 cells and SARS patients. J Mol Biol 341:271–279 [CrossRef]
    [Google Scholar]
30. Zhao P., Ke J.-S., Qin Z.-L., Ren H., Zhao L.-J., Yu J. G., Gao J., Zhu S.-Y., Qi Z.-T. 2004; DNA vaccine of SARS-Cov S gene induces antibody response in mice. Acta Biochim Biophys Sin 36:37–41 [CrossRef]
    [Google Scholar]
31. Zhong X., Yang H., Guo Z.-F. & 13 other authors 2005; B-cell responses in patients who have recovered from severe acute respiratory syndrome target a dominant site in the S2 domain of the surface spike glycoprotein. J Virol 79:3401–3408 [CrossRef]
    [Google Scholar]